

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE **RECEIVED**

OCT 28 2002

TECH CENTER 1600/290

P#7

Applicants: Collins, D.A. *et al.*

Serial No.: 10/027,593

Group Art Unit: 1614

Filed: October 25, 2001

Examiner: Not Yet Assigned

For: Transcobalamin Binding Conjugates Useful for Treating Abnormal Cellular Proliferation

Assistant Commissioner for Patents
Washington, DC 20231

October 18, 2002

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publication listed on the accompanying Form PTO-1449A. A copy of the reference is enclosed as well as a copy of the PCT Search Report. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise.

If the Examiner determines a fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to Deposit Account No. 11-0980.

Respectfully submitted,

Hoang M. Vo

Registration No. 47,158

KING & SPALDING
191 Peachtree Street
Atlanta, GA 30303
404-572-4600 (Telephone)**BEST AVAILABLE COPY**




RECEIVED

OCT 28 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.


Hoang M. Vo

Date: October 18, 2002

BEST AVAILABLE COPY


Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <div style="text-align: center;">  INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i> </div>				Complete if Known	
		Application Number	10/027,593		
		Filing Date	October 25, 2001		
		First Named Inventor	Collins, D.A. <i>et al.</i>		
		Group Art Unit	N/A		
		Examiner Name	N/A		
		Attorney Docket Number	COP 1008 US		
Sheet	1	of	1		

RECEIVED

OCT 28 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document DD-MM-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Office ³	Number	Kind Code ² (if known)				
		WO	96/04016		Amgen Inc.	15-02-1996		
		WO	94/27641		BioTech Australia	08-12-1994		
		WO	00/45857		Schering	10-08-2000		
		WO	02/42318		Collins	30 May 2002		
		WO	01/92288		Collins	06-12-2001		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
			T ⁶

BEST AVAILABLE COPY

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.